The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

ESH 2019 | What are the new concepts to target cancer stem cells in AML?

Nov 1, 2019

The AML Global Portal were delighted to speak to Ravi Majeti, Stanford University School of Medicine, Stanford, US, during the European School of Hematology (ESH) Translational Research Conference on AML. We asked Ravi Majeti: What are the new concepts to target cancer stem cells in AML?

Ravi Majeti discusses different targets for therapies in AML. These include the self-renewal signaling pathways (e.g. Hedgehog and Wnt) and immunological approaches (e.g. targeting cell surface receptors like CD123 with chimeric antigen receptor [CAR] T-cell therapy). He also raises questions regarding the role of measurable residual disease (MRD).

What are the new concepts to target cancer stem cells in AML?